Belimumab, a monoclonal antibody targeting the soluble circulating BAFF, proved especially useful in APS patients with high thrombotic risk or aPL–antibody-positive patients with microthrombotic complications [131]. This evidence concerns the gene TNFSF13B and autoimmune polyendocrinopathy.